Y-Mabs Therapeutics Inc
NASDAQ:YMAB
| Market Cap (Intraday) | 662.37M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $14.90 |
| 50-Day MA | $15.64 |
| 200-Day MA | $8.80 |
Y-Mabs Therapeutics Inc Stock, NASDAQ:YMAB
230 Park Avenue, Suite 3350, New York, New York 10169-0005
United States of America
Phone: +1.646.885.8505
Number of Employees: 100
Description
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.